SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the... Read More

SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA The value of the transaction is up to $52.5 million , including cash, milestone payments and litigation credits. Natera has hired Invitae reproductive... Read More

Maintains Minority Equity Stake in Ciitizen Anticipated Total Cash Savings of Approximately $90 -100 Million on an Annualized Basis SAN FRANCISCO , Dec. 13, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash burn. The company has divested the assets of Ciitizen and announced strategic cost cuts, which will include... Read More

Reported revenue of $121.2 million , a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4% Gross margin of 32.2% and non-GAAP gross margin of 52.4%; continued improvement in non-GAAP gross margin for nine consecutive quarters Reaffirming 2023 financial guidance SAN FRANCISCO , Nov. 8, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a... Read More

Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies May provide real-time data on therapy response, support patient prognostic stratification and enable early detection of residual disease SAN FRANCISCO , Nov. 6, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced enhanced chemistry of its Invitae... Read More

SAN FRANCISCO , Nov. 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 , and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register here . Upon... Read More

Findings set to enhance patient care and reduce uncertainty in test results as clinicians advance precision healthcare for hereditary disease SAN FRANCISCO , Oct. 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from the largest study to date on uncertain results from hereditary disease genetic testing. Published in JAMA Network Open , the study evaluated data from... Read More

SAN FRANCISCO , Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar , M.D., as chief operating officer, effective November 13, 2023 . Dr. Sholehvar is a healthcare business leader with a 25-year track record of successfully solving complex problems and leading business transformations, addressing regulatory... Read More

Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines Testing results informed clinical management and suggest that genetics-informed care may improve patient outcomes and optimize resource utilization SAN FRANCISCO , Oct. 12 , 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced results of its collaborative study on universal... Read More

Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care These studies combined with new digital tools aim to increase access and frequency of hereditary cancer screening both before and during treatment SAN FRANCISCO , Oct. 10, 2023 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society... Read More

First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category Testament to Invitae's product and lab quality Sets the bar for expected performance and the associated data required for future regulatory approval of similar products SAN FRANCISCO , Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA... Read More

SAN FRANCISCO , Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2 . Robert Dickey , who has been the Company's interim CFO since August 2023 , will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team... Read More

SAN FRANCISCO , Sept. 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on September 20, 2023 , indicating the company is not currently in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock over a consecutive 30 trading-day... Read More

Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth SAN FRANCISCO , Aug. 28 , 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023 . Mr. Guigley brings to the role more than 20 years of commercial... Read More

Research published in European Urology Oncology shows restrictive genetic testing criteria miss a significant number of prostate cancer patients with potentially actionable inherited variants Offering germline testing to all prostate cancer patients could improve access to critical genetic information, particularly for historically underrepresented groups SAN FRANCISCO , Aug. 15, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a... Read More

Christine Gorjanc resumes role as Chair of the Audit Committee of the Board of Directors for Invitae SAN FRANCISCO , Aug. 14, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Robert Dickey has been named its interim chief financial officer (CFO), effective immediately. Christine Gorjanc , who had assumed the interim CFO role in June 2023 , will transition back to her prior... Read More

Reported revenue of $120.5 million , a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters Company improves ongoing cash burn annual guidance to $220 - $245 million ; adjusts 2023 revenue guidance to $480 - $500 million... Read More

SAN FRANCISCO , July 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 , and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below:... Read More

SAN FRANCISCO , May 31, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight , president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023 , at 12:40 p.m. Central Time . A live audio webcast of the presentation may be accessed by visiting the investors section of the company's website at... Read More

Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care SAN FRANCISCO , May 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 2-6, 2023 . The new... Read More

SAN FRANCISCO , May 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023 . The Company has initiated a search for a new CFO. Ms. Wen will continue in her role through the end of the second quarter. Christine Gorjanc , the Company's longtime Chair of the Audit... Read More

SAN FRANCISCO , May 15, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the District of Delaware . The jury found that Invitae's products using Anchored Multiplex PCR ("AMP") chemistry infringe certain Natera, Inc. patents. The jury awarded Natera a total of $19.35 million , based... Read More

Reported revenue of $117.4 million , a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% Continued improvement in gross margin and ongoing cash burn trends Company reiterates key 2023 financial guidance metrics Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time SAN FRANCISCO , May 9, 2023 /PRNewswire/ -- Invitae (NYSE:... Read More

SAN FRANCISCO , April 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 , and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below:... Read More

Report details the company's commitment to improve healthcare for all through its ESG and sustainability initiatives SAN FRANCISCO , April 17, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today published its 2023 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and our performance and progress through measurable data and... Read More

Highlights the use of Invitae's personalized cancer monitoring (PCM) technology to correlate clinical outcomes with minimal residual disease (MRD) presence The analysis demonstrates the utility of ctDNA as a highly sensitive and specific biomarker for cancer recurrence Study validates the need for MRD assays; the company to continue to leverage its differentiated PCM technology in pursuing opportunities across multiple... Read More

The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients SAN FRANCISCO , March 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company , a healthcare investment firm, today announced a partnership to advance genetics-based... Read More

Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine SAN FRANCISCO , March 21, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company. Through Aura, Epic's specialty diagnostics suite, Invitae will streamline interactions with... Read More

Expert in the field of gastrointestinal cancer and precision oncology to lead Invitae's medical oncology team with a particular focus on somatic testing development Invitae reports inducement grant under NYSE Rule 303A.08 SAN FRANCISCO , March 16, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of W. Michael Korn , M.D., as its chief medical officer for oncology,... Read More

New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic testing SAN FRANCISCO , March 15, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be presented at the 2023 American Clinical Genetics Meeting held in Salt Lake City from March... Read More

Blue Shield of California has over 3 million covered members in CA SAN FRANCISCO , March 6, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California . The policy, effective as of... Read More

SAN FRANCISCO , March 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight , president and chief executive officer, will participate in a fireside chat at the TD Cowen 43 rd Annual Health Care Conference on Monday, March 6 , at 1:30 p.m. Eastern. A live audio webcast of the fireside chat may be accessed by visiting the investors section of the company's website at... Read More

In a transaction led by Deerfield Management, the Company effectively addresses ~96% of its 2024 convertible debt obligations Participating holders to exchange 90% of their existing 2024 notes for new notes due in 2028 and equitize 10% of their holdings; Certain investors will also provide an additional $30 million of capital The Company will discuss this announcement during its fourth quarter and full year 2022 earnings... Read More

Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding (see separate press release to follow) Repaid its 2024 senior secured term loan in full, improving its balance sheet Company maintains cash runway through the end of 2024 Annual revenue grew by 12.1%; Continued to improve on key financial metrics Major initiatives under strategic realignment largely... Read More

Approximately 12% growth year-over-year in revenues Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash Cash burn continued its declining trend over the past five quarters Presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 9:00 a.m. PST SAN FRANCISCO , Jan. 9, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today... Read More

SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight , president & chief executive officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 , at 12:00 p.m. Eastern / 9:00 a.m. Pacific. The live audio webcast of the presentation may be accessed by visiting the investors section of the company... Read More

Invitae will continue to invest in its precision oncology focused lab developed test (LDT) offerings The transaction contributes to Invitae's cash runway and includes a strategic supply partnership to support the growth of Invitae Personalized Cancer Monitoring™ (PCM) services SAN FRANCISCO , Dec. 20, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has completed a... Read More

Deven McGraw to serve a 3-year term beginning in 2023 SAN FRANCISCO , Dec. 19, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, announced the appointment by the U.S. Government Accountability Office (GAO) of Deven McGraw , lead of data stewardship and data sharing at Invitae, to the National Health Information Technology Advisory Committee (HITAC). Established as part of the 21st Century Cures... Read More

Invitae to report on secondary patient data use, demonstrating real-world impact of de-identified patient data on the advancement of precision medicine Company achieves over 1 million ClinVar submissions to advance science and patient care SAN FRANCISCO , Dec. 7, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the release of its Data Use Transparency and Impact Report, which... Read More

Ciitizen real-world data platform expansion helps advance research and potentially improve outcomes for patients with pediatric epilepsy and/or developmental delay SAN FRANCISCO , Dec. 1, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae's Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay... Read More